UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 29, 2018

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

Nevada	000-53605	26-1265381
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
400 Water Street, Suite 200, Rocheste	r, MI	48307
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code: <u>24</u>	8.651.6568	
(Former name or former address, if changed since last report)		
Check the appropriate box below if the Form 8-K filing provisions:	s is intended to simultaneously satisfy the filing	obligation of the registrant under any of the following
☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)		
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
Indicate by check mark whether the registrant is an eme or Rule 12b-2 of the Securities Exchange Act of 1934 (of the Securities Act of 1933 (§230.405 of this chapter)
Emerging growth company \Box		
If an emerging growth company, indicate by check mar revised financial accounting standards provided pursua	S .	nded transition period for complying with any new or

SECTION 8 – Other Events

Item 8.01 Other Events

On August 29, 2018, we issued a press release about our invitation to participate at the Lake Street Capital Market's 2018 Best Ideas Growth (BIG) Conference being held on September 13, 2018 at the Parker New York Hotel in NYC.

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SECTION 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

99.1 Press release, dated August 29, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OptimizeRx Corporation

/s/ Douglas Baker
Douglas Baker
Chief Financial Officer
Date August 29, 2018



OptimizeRx to Participate at Lake Street Capital Markets Best Ideas Growth Conference on September 13, 2018

ROCHESTER, Mich., August 29, 2018 — OptimizeRx Corp. (OTCQB: OPRX), a leading global provider of digital health messaging for the pharmaceutical industry, has been invited to participate at the Lake Street Capital Market's 2018 Best Ideas Growth (BIG) Conference being held on September 13, 2018 at the Parker New York Hotel in NYC.

OptimizeRx CEO William Febbo is scheduled to participate in one-on-one meetings. He will discuss a number of topics, including the company's record Q2 results and additional reach to physicians at the point-of-care workflow helping patients better afford and comply with doctor-prescribed medications. He will also discuss the company's growing network, the largest network of its kind, that reaches more than half of the ambulatory patient market in the U.S.

The Lake Street 2018 BIG Conference will give investors extensive interaction and one-on-one meetings with management teams from ~45 small/mid-cap companies in the health care, technology, consumer and industrials sectors, and provide in-depth insights into each of them.

The event is for institutional clients of Lake Street and is by invitation only. To schedule a one-on-one meeting with OptimizeRx, please contact your Lake Street sales representative at (612) 326-1305 or conference@lakestreetcm.com. For any questions about OptimizeRx, contact Ron Both of CMA at (949) 432-7557 or submit your request here.

About Lake Street Capital Markets

Lake Street Capital Markets is a research-powered investment bank focused on select, high-growth companies and sectors of the economy. The company's research enables institutional investors to understand emerging secular trends and identify innovative companies best positioned to capitalize on them. Lake Street provides companies with access to capital and helps build relationships to drive long-term growth. For more information on Lake Street, please visit www.lakestreetcapitalmarkets.com.

About OptimizeRx

OptimizeRx® (NASDAQ: OPRX) is one of the nation's leading providers of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company's cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company's network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half of the ambulatory patient market with access to these benefits within their workflow at the point-of-care. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact:

Doug Baker, CFO Tel (248) 651-6568 x807 dbaker@optimizerx.com

Investor Relations Contact:

Ron Both, CMA Tel (949) 432-7557 Email contact